US 10918668
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
granted A61KA61K2239/38A61K2239/48
Quick answer
US patent 10918668 (Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases) held by Sangamo Therapeutics, Inc. expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K2239/38, A61K2239/48, A61K35/26, A61K40/11